Lexicon Pharmaceuticals (LXRX) to Release Earnings on Thursday

Lexicon Pharmaceuticals (NASDAQ:LXRX) is set to issue its quarterly earnings data after the market closes on Thursday, August 1st. Analysts expect the company to announce earnings of ($0.18) per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.02). The business had revenue of $1.13 million during the quarter, compared to analyst estimates of $1.17 million. Lexicon Pharmaceuticals had a negative return on equity of 108.54% and a negative net margin of 8,311.12%. On average, analysts expect Lexicon Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Lexicon Pharmaceuticals Trading Down 2.6 %

Shares of NASDAQ:LXRX traded down $0.06 during trading on Tuesday, hitting $2.24. The company’s stock had a trading volume of 1,066,964 shares, compared to its average volume of 3,647,052. The business has a 50 day moving average price of $1.83 and a two-hundred day moving average price of $2.00. The company has a debt-to-equity ratio of 0.35, a quick ratio of 15.56 and a current ratio of 15.58. Lexicon Pharmaceuticals has a fifty-two week low of $0.92 and a fifty-two week high of $3.73.

Analyst Upgrades and Downgrades

LXRX has been the subject of several research reports. SVB Leerink initiated coverage on shares of Lexicon Pharmaceuticals in a research note on Tuesday, April 30th. They issued an “outperform” rating and a $5.00 price target for the company. Leerink Partnrs restated an “outperform” rating on shares of Lexicon Pharmaceuticals in a research note on Tuesday, April 30th. StockNews.com raised shares of Lexicon Pharmaceuticals to a “sell” rating in a research report on Tuesday, July 9th. Needham & Company LLC reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Friday, May 3rd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Lexicon Pharmaceuticals in a research report on Tuesday, July 16th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $6.67.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.